We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Marks Electrical Group Plc | MRK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 70.00 | 08:00:26 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 70.00 | 70.00 | 71.75 | 70.00 | 70.00 |
| Industry Sector |
|---|
| HOUSEHOLD GOODS & HOME CONSTRUCTION |
| Top Posts |
|---|
Posted at 22/11/2023 15:07 by edmonda Video recording now available - Investor Presentation with Q&A (Interim Results)Marks Electrical Group, the fast-growing online electrical retailer, conducted an investor webinar following publication of their Interim Results. Mark Smithson (founder & Chief Executive Officer) and Josh Egan (Chief Financial Officer) ran investors through key details of their HY24 numbers which included strong revenue growth and the impact of distribution & installations costs on margin. Management discussed their expanded geographic presence and the roll-out of their next-day installation offering, as well as their strong balance sheet and cash generation. There was also a wide-ranging Q&A session following the presentation. The full video has been divided into chapters, as below: 0:00:03 Key highlights from HY24 0:03:00 Financial overview 0:10:51 Strategic update 0:24:14 Summary & Outlook 0:24:50 Questions & Answers Link to full video: |
Posted at 05/9/2023 10:40 by darrin1471 Increasing volumes were noted on this thread at the end of June.Also worth noting post 76 where I reported that Mark had said he was willing to sell some of his 73.6% once the share price was above the IPO. Speculation: If I was trying to build a stake in MKS I would have been in contact with Mark or MKS's broker to register my interest and a price. I would then be trying to add as much as I could at a price below the IPO. We may be stuck below IPO price until a buyer has got near a disclosable stake. If Mark sells a chunk of his 73.6% then that is when I think we could see a pop. What percentage will Mark sell? Taking it below 50% may be seen as a positive. When I have spoken to other small investors, the most common concern about MKS is that Mark could delist and take it private again as he has such a large holding. |
Posted at 17/6/2023 09:53 by cf456 If investors are keen to buy after the recent results (and the initial upwards move in price would seem to suggest that they are), then the continued tight free float is a good thing in that there is limited supply around and the price will move up quickly with even a small level of demand.Instis buying a portion of the CEO’s holding above the 110p IPO price would help with future liquidity. The share price has started moving again after a multi month sideways base. 120p looks to be a reasonable short term target. Of course over the longer term the CEO has stated that he’s looking for revenues of £500m, more than 5x current revs, so a lot of share price upside potential if that comes to pass. |
Posted at 16/6/2023 17:31 by darrin1471 I asked Mark on the "online presentation for investors" if he would be willing to sell some of his holding which is currently 73.6%.He answered without hesitation which implied he had already given it some thought. Mark said he knows he needs to reduce but would not do so below IPO price in fairness to IPO shareholders. There is only 12m shares available outside of major shareholders, so anyone wanting a decent stake will need to buy up to the IPO price of 110p. Not sure if 110p will act as a ceiling or a catalyst to kick on |
Posted at 21/8/2022 14:05 by darrin1471 I took a look at MRK last week. I read this thread, investor information and the online interviews with Mark and Josh.My thoughts, are a little jumbled Mark Smithson is an entrepreneur, a salesman and somebody who cares about his business. Not necessary somebody who I would want running a more complicated business. In FY22 MRK had 1.6% market share of a £5.3 billion major domestic appliances market (MDA)and they are targeting a 10% market share. John Lewis have a 15% market share. MRK are starting to sell into the £3b UK consumer electronics market (CE) and currently have a 0.21% market share. After rapid growth 2020 £31m 2021 £56m 2022 £80m growth is forecast to rise at more sustainable levels 2023 £94m 2024 £112m MRK are targeting £500m. Current warehouse site capacity is £250m MRK are not targeting the whole of the MDA market. MRK target the ABC1 customer with higher average selling prices and fewer after sales issues. Premium brands. Top 5 by sales are Bosch, Samsung, Rangemaster, Neff & LG. MRK do not sell own brands imported direct from China MRK are price competitive offering next day delivery from Newcastle to Exeter with a new biweekly delivery to Cornwall, Cumbria, Glasgow and Edinburgh. MRK USP is their next day delivery using their own vans from a single warehouse in Leicestershire. Long term expansion will not include multiple warehouse locations. Customer service is very important to Mark Smithson and results in a 4.8 Trustpilot score. A score he is very proud of and which MRK follows up on every negative review where possible. Current adjusted EBITDA of 9% is maintainable. FY22 adjusted eps 5.01p. Dividend 0.67p. "with the 0.67p being a typical two-third share of the annualised amount" "it is the Board’s intention to pursue a progressive dividend policy and target a pay-out ratio, being the annual total dividend per share divided by earnings per share for the year, of up to 20 per cent." IPO placed 27.3m at £1.10. Mark Smithson retains 73.6%. Octopus bought 3.9% and Canaccord took 5.24% leaving 18m in circulation which may result in an illiquid share and volatile movements if somebody wants to add/sell stock. Mark Smithson retains ownership of warehouse and it is leased to MRK for £600k pa for 52 months ending 30/09/2024 Mkt cap at IPO was £115m and is currently £71m IPO was well timed and valued as a company with good growth potential. 20% annual growth would be £250m year 5 and £500m year 9 Retail has been trashed ytd and MRK has followed the market. Group’s sales for the recent trading update. Revenue "first four months up 13.7% compared with the online MDA and CE markets being down over 20% in the first months of our FY23." More of the growth came from volume increases than price increases. "80% of Marks Electrical revenue is from distressed purchases" i.e. broken and needs replacing. Stock shortages eased from April/May. Peak prices reached. Offers now being given as manufacturers need to clear. Increased fuel costs not material. Other additional costs include NI, PLC costs and normal business rates environment. "lean keen business model" "not growth at all costs" Marketing budget is 5% of sales to improve sales and brand awareness. Suppliers for the first time are looking to share marketing costs with MRK. MRK brand awareness is still only 7%. Future costs of new larger semi automated warehouse could be a drain on cash. Competitor AO could improve customer service and delivery times. Retail stores can not compete with online costs. MRK sees inhouse IT as a competitive advantage but does this increase risk to cyber security. Part of buying group. |
Posted at 11/4/2022 08:40 by brummy_git Investor update video with CEO Mark Smithson herewww.voxmarkets.co.uk |
Posted at 11/4/2022 07:37 by brummy_git Fabulous Q4'22 results from Marks Electrical today.Find out all the details & investor interpretation here. www.linkedin.com/pos |
Posted at 14/2/2022 17:30 by leoinvestoruk Mark Smithson (Founder / CEO) and Josh Egan (CFO) will be live and in person at the Small Caps Live Midlands investor meet on the 23rd March for a presentation plus Q&A.Details and registration here: |
Posted at 06/11/2021 10:50 by hedgehog 100 Current share price 6th. November 2021: 110.5pMarket capitalisation: £115.97M. "ABOUT US For over 30 years, Marks Electrical have been selling the best of appliances and televisions to over a million satisfied customers. Since 1987, we've provided high-quality products at competitive prices and we stand today as an independent elite retailer and member of Euronics. We pride ourselves on our achievements and the accolades we've been honoured to accept, including Best Website at the IER Awards. Further success is our driving force." "Investment case In FY21, we had 1.2% market share of a £5.3 billion major domestic appliances market…" Marks Electrical Grp Placing and Proposed Admission to Trading on AIM RNS Number : 0417R Marks Electrical Group plc 02 November 2021 "Marks Electrical, a fast growing online electrical retailer, announces its proposed admission to trading on AIM ("Admission") and its successful placing, conditional on Admission, (the "Placing") of 4,545,454 new ordinary shares (the "New Shares") and 22,727,273 existing ordinary shares (the "Sale Shares") of 1 pence each in the capital of the Company (the "Shares") both at a price of 110 pence per Share (the "Placing Price") with institutional and other investors. ... · Based on the Placing Price, the market capitalisation of the Company will be approximately £115 million on Admission. · On Admission, the Company will have 104,949,050 Shares in issue and a free float of approximately 25.9 per cent. · The Placing attracted strong support from high quality institutional investors and was over-subscribed. · The Placing of 4,545,454 New Shares is expected to raise approximately £2.6 million after deduction of commissions and expenses ("net proceeds"). · The net proceeds will provide the Company with sufficient cash reserves for potential future investments in capacity enhancement, including additional vehicle capacity to continue scaling-up, as well as the costs associated with moving to larger premises when growth has outstripped the capacity of the existing premises and any leasehold improvements that may be necessitated by such a move. · The Placing of the Sale Shares is expected to raise gross proceeds of £25.0 million for the Selling Shareholder. ..." 05/11/2021 07:00 UK Regulatory (RNS & others) Marks Electrical Group plc Admission to AIM and First Day of Dealings LSE:MRK Marks Electrical Group Plc "Marks Electrical, a fast growing online electrical retailer, is pleased to announce the admission of its entire issued and to be issued share capital to trading on the AIM market of the London Stock Exchange. Admission will take place and dealings will commence at 8.00 a.m. today under the ticker MRK and ISIN GB00BM8Q5G47. The Company's Admission Document is available to view on the Company's website at group.markselectrica Mark Smithson, Founder & Chief Executive Officer of Marks Electrical, commented: "Our admission to AIM is an exciting milestone for Marks Electrical. The successful completion of our IPO represents the beginning of a new chapter as we continue to scale the business and grow our share of the huge online retail market for home appliances. "I am delighted to welcome our new shareholders and would like to thank them for their support. We look forward to working with them in the years ahead as we build on our strong momentum and push forward with our ambitious growth plans." ... Marks Electrical sells, delivers, installs and recycles a wide range of household electrical products. The Marks Electrical group was founded in Leicester in 1987 by its Chief Executive Officer, Mark Smithson, and has expanded into a nationwide online retailer, with a strong track record of growth and scaling the business as a result of the consumer shift to online shopping. Primarily through its retail website - markselectrical.co.u In the year to 31 March 2021 ("FY2021") revenue grew to GBP56 million, up 78% against the previous financial year, while EBITDA increased to GBP7.70 million, at a 13.8% EBITDA margin. The Group has made a strong start to its current financial year to 31 March 2022 ("FY2022"), with revenue growth of 78% in H1 FY2022, versus 47% growth in H1 FY2021. ..." |
Posted at 09/10/2009 06:33 by ariane PRESS RELEASE: Dose-Finding Phase IIb Study Started In Patients With Multiple Sclerosis - Actelion/Roche S1P1 Alliance Achieves (Actelion Ltd)Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. =------------------- =------------- ALLSCHWIL, SWITZERLAND - 09 October 2009 - Actelion Ltd (SIX: ATLN) announced today that the selective S1P1 receptor agonist ACT-128800/ RG3477 has achieved an important clinical milestone. Actelion's first-in-class selective S1P1 (Sphingosine-1-phosp agonist has entered into a Phase IIb dose-finding study in patients suffering from multiple sclerosis. This triggers a milestone payment by Roche to Actelion of USD 20 million. Guy Braunstein, M.D., Ph.D. and Head of Clinical Development at Actelion, commented: "Together with our partner Roche, we are committed to the rapid development of our selective S1P1 receptor agonist for patients suffering from autoimmune disorders. With the start of this dose-finding study in patients with multiple sclerosis, we have made an important step forward." About the Actelion / Roche alliance Actelion and Roche entered into an exclusive worldwide collaboration in July 2006 to jointly develop and commercialize Actelion's selective S1P1 receptor agonist, an immunomodulator with the potential for once-a-day oral dosing. The two companies plan to jointly develop and commercialize this novel compound for multiple autoimmune disorders. For the current selective S1P1 receptor agonist, Actelion will fully fund all development activities up to the end of Phase II for the first two indications. All subsequent development and commercialization costs will be shared equally between Roche and Actelion. Both companies will co-promote any product resulting from this collaboration and will equally share profit. This S1P1 collaboration covers both the current selective S1P1 receptor agonist in clinical development, as well as any other selective S1P1 receptor agonists resulting from Actelion's research efforts in the field. Actelion received an upfront payment of USD 75 million in July 2006. In the case of future development and approval milestones being achieved, Actelion will be eligible to receive further payments of up to USD 535 million for the first compound for all targeted indications. Further development and approval milestone payments are due for additional compounds. Roche will pay Actelion undisclosed royalties on all product sales. Selective S1P1 receptor agonists Sphingosine-1-phosph platelets, mast cells and other cells. It is currently established [1,2] that S1P stimulates at least five different G-protein coupled receptors (GPCRs): S1P1,2,3,4, and 5. Activation of these GPCRs mediates a complex variety of biological responses, such as lymphocyte migration, endothelial cell proliferation, blood vessel constriction and heart rate modulation. Actelion's efforts in the field of selective S1P1 receptor agonists started in 1999 by focusing on GPCRs found on the endothelium, the inner lining of blood vessels. The result of these research efforts is Actelion's orally active selective S1P1 receptor agonist. ### Notes to the editor About autoimmune disorders Autoimmune disorders are diseases caused by the body producing an immune response against its own tissues. The cause of autoimmune disorders is unknown. Some of the most common types of autoimmune disorders include psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and rejection of transplanted organs. These disorders affect millions of people worldwide. About multiple sclerosis Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system (CNS) and is the most common cause of progressive neurological disability in young adults [3,4]. This chronic demyelinating disease is characterized by heterogeneous clinical expression, an unpredictable course and a variable prognosis. MS results from a cascade of events involving an activation of the immune system, acute focal inflammatory demyelination, and axonal loss with limited remyelination, culminating in chronic multifocal sclerotic plaques in brain and spinal cord. The large variety of symptoms and signs of MS result from axonal demyelination which leads to the slowing or blockade of axonal conduction at diverse affected sites of the brain and spinal cord. Repeated episodes of disease activity may lead to progressive loss of neurological function. The incidence of MS is about 7 cases per 100,000 persons per year and although the etiology of MS is still unknown, the prevalence rate varies between races and geographical latitudes, ranging from 50-120 per 100,000 [3]. It is widely accepted that it is an immune-mediated, demyelinating disease precipitated by unknown environmental factors in genetically susceptible people. References 1. Huwiler A, Pfeilschifter J. Biochem Pharmacol. 2008 May 15;75(10):1893-900. Review. 2. Rivera J, Proia RL, Olivera A.Nat Rev Immunol. 2008 Oct;8(10):753-63. Review. 3. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31. 4. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-18. Actelion Ltd Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2000 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN). For further information please contact: Roland Haefeli Vice President, Head of Investor Relations & Corporate Communications Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36 =-- End of Message --- Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland WKN: 936767; ISIN: CH0010532478; Index: SBIOM, SLIFE, SMCI, SMIEXP, SMIM, SPI, SPIEX; Listed: Main Market in SIX Swiss Exchange; Copyright © Hugin AS 2009. All rights reserved |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
